General Counsel Smith Jason Drew converted options into 15,500 units of Ordinary Shares and sold $147,262 worth of Ordinary Shares (7,479 units at $19.69), increasing direct ownership by 11% to 55,588 units (SEC Form 4)
$URGN
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 01/31/2026 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Ordinary Shares | 01/31/2026 | M | 5,500 | A | (1) | 55,472 | D | |||
| Ordinary Shares | 02/03/2026 | S | 2,654(2) | D | $19.69 | 52,934 | D | |||
| Ordinary Shares | 01/31/2026 | M | 3,333 | A | (1) | 58,805 | D | |||
| Ordinary Shares | 02/03/2026 | S | 1,608(2) | D | $19.69 | 51,326 | D | |||
| Ordinary Shares | 01/31/2026 | M | 6,667 | A | (1) | 49,972 | D | |||
| Ordinary Shares | 02/03/2026 | S | 3,217(2) | D | $19.69 | 55,588 | D | |||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Restricted Stock Units | (1) | 01/31/2026 | M | 5,500 | (5) | (5) | Ordinary Shares | 5,500 | $0 | 5,500 | D | ||||
| Restricted Stock Units | (1) | 01/31/2026 | M | 3,333 | (3) | (3) | Ordinary Shares | 3,333 | $0 | 6,667 | D | ||||
| Restricted Stock Units | (1) | 01/31/2026 | M | 6,667 | (4) | (4) | Ordinary Shares | 6,667 | $0 | 0 | D | ||||
| Restricted Stock Units | (1) | 01/31/2026 | A | 32,609 | (6) | (6) | Ordinary Shares | 32,609 | $0 | 32,609 | D | ||||
| Explanation of Responses: |
| 1. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. |
| 2. Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. |
| 3. The reporting person was granted RSUs on January 31, 2025 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2026. |
| 4. The reporting person was granted RSUs on January 31, 2023 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024. |
| 5. The reporting person was granted RSUs on January 31, 2024 representing 16,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025. |
| 6. 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029. |
| /s/ Jason D. Smith, Attorney-in-Fact | 02/11/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||